Clik here to view.
Swift Biosciences发布业界领先的新款标引接头，单次运行可测序的样本更多
密歇根州安娜堡 (美国商业资讯) — Swift Biosciences是面向基因组测序的创新文库制备解决方案的领先提供商，该公司今天宣布上市Accel-NGS®...
View ArticleClik here to view.
スウィフト・バイオサイエンシズ、1回のランで多数のサンプルをシーケンスできる業界最高レベルの新しいインデックス付きアダプターを発表
米ミシガン州アナーバー （ビジネスワイヤ）–ゲノムシーケンス用の革新的なライブラリー調製ソリューションを提供する一流のスウィフト・バイオサイエンシズは本日、Accel-NGS® 2Sインデックス付きアダプターの市場投入を発表しました。Accel-NGS®...
View ArticleClik here to view.
GEN1 Biotechnology Raises AUD$8m (USD$6.3m)
ADELAIDE, Australia GEN1 Biotechnology Pty Ltd, a biopharmaceutical manufacturer based in Adelaide, Australia, has completed an AUD$8m (USD$6.3m) funding round, with an expected closing during...
View ArticleClik here to view.
FDA同意WIN联合会启动3种靶向药物用于转移性非小细胞肺癌一线治疗的临床试验
法国维勒瑞夫 (美国商业资讯) — 美国食品药品管理局(FDA)已核准WIN联合会(WIN)启动一种新型治疗方法的临床研究，该方法采用3种靶向药物联合，用于晚期非小细胞肺癌(NSCLC)患者的一线治疗。该研究名称为“理性创新基因组学延长生存期” (Survival Prolongation by Rationale Innovative Genomics,...
View ArticleClik here to view.
WINコンソーシアムが転移性非小細胞肺がんのファーストライン治療での分子標的薬3剤併用療法の臨床試験開始の承認をFDAより取得
仏ビルジュイフ （ビジネスワイヤ） — WINコンソーシアム（WIN）は、米食品医薬品局（FDA）より、進行性非小細胞肺がん（NSCLC） 患者のファーストライン治療で3種類の分子標的治療薬の組み合わせを使用した新規治療アプローチに対し、臨床試験開始の承認を受けました。SPRING（Survival Prolongation by Rationale Innovative...
View ArticleClik here to view.
Takeda and Shattuck Labs Announce Research Collaboration to Explore Agonist...
CAMBRIDGE, Mass. & AUSTIN, Texas Takeda Pharmaceutical Company Limited (TSE: 4502) and Shattuck Labs, Inc. announced today that they have entered into a research collaboration to explore and...
View ArticleClik here to view.
CDISC Releases Therapeutic Area User Guide to Assist in Discovery of New...
AUSTIN, Texas According to the World Health Organization, prostate cancer is one of the five most common types of cancer to affect men globally. In an effort to improve research for prostate cancer,...
View ArticleClik here to view.
Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage...
SAN DIEGO Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces that it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of...
View ArticleClik here to view.
PAREXEL and Osaka International Cancer Institute Form Alliance to Advance...
BOSTON & OSAKA, Japan PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they...
View ArticleClik here to view.
20/20’s Lung Cancer Detection Technology Launches in China
ROCKVILLE, Md. & SHANGHAI 20/20 GeneSystems, Inc. (www.2020gene.com) (“20/20”) released this week in China what is believed to be the world’s first machine learning algorithm commercialized for...
View ArticleClik here to view.
Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and...
View ArticleClik here to view.
Celularityが画期的な胎盤発見＆治療プラットフォームの開発を促進
米ニュージャージー州ウォーレン （ビジネスワイヤ） — 最近創業したバイオテクノロジー企業のCelularity,...
View ArticleClik here to view.
Celularity, Inc.加快突破性胎盘发现和治疗平台
新泽西州沃伦 (美国商业资讯) — Celularity, Inc.是一家新成立的生物技术公司，该公司今天宣布，它在加快细胞及组织再生治疗药物，以满足癌症和慢性及退行性疾病领域未获满足的医疗需求。Celularity已完成A轮融资，投资方来自数家生物制药公司，包括Sorrento Therapeutics、United Therapeutics Corporation和Human...
View ArticleClik here to view.
Astex Pharmaceuticals Celebrates as Cancer Drug Receives Marketing Approval...
CAMBRIDGE, England Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central...
View ArticleClik here to view.
Kyowa Hakko Kirin Co., Ltd.: US Food and Drug Administration Grants...
TOKYO Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151)(President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announced that U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
View ArticleClik here to view.
MOLOGEN AG and Chinese iPharma Ltd. signed binding term sheet for a...
BERLIN The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today the signing of a binding term sheet that defines the framework for...
View ArticleClik here to view.
Study Evaluates Utility of Masimo SpHb® During High-Blood-Loss Oncosurgery
NEUCHATEL, Switzerland Masimo (NASDAQ:MASI) announced today the findings of a recently published study in which researchers in New Delhi, India evaluated the utility of Masimo SpHb®, noninvasive,...
View ArticleClik here to view.
KYOCERA Begins Research in AI-based Image Recognition to Help Diagnose Skin...
KYOTO, Japan Kyocera Corporation (NYSE:KYO)(TOKYO:6971) announced today that its subsidiary, Kyocera Communication Systems Co., Ltd. (hereafter “KCCS”), has started joint research with the...
View ArticleClik here to view.
研究评估Masimo SpHb®在高失血量肿瘤手术中的功用
瑞士纳沙泰尔 (美国商业资讯) — Masimo (NASDAQ:MASI)今天发布了印度新德里研究人员最新发表的一项研究结果，该研究评估Masimo无创连续血红蛋白测量指标SpHb®在预期高失血量的肿瘤手术患者中的功用1。...
View ArticleClik here to view.
失血量が多い腫瘍手術中における研究でMasimo SpHb®の有用性を評価
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、インドのニューデリーの研究者らが最近発表した研究の知見について発表しました。この研究は、大量の失血が予想される患者を対象に、非侵襲的かつ連続的なヘモグロビン測定値であるMasimo SpHb®の腫瘍手術中における有用性を評価したものです1。...
View Article